Clinical Trial Update: A Study of DeTIL-0255 in Adults With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of DeTIL-0255 in adults with advanced cancers (ovarian, endometrial, and cervical cancer) sponsored by Nurix Therapeutics has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• DeTIL-0255

Snippet

Sponsor: Nurix Therapeutics, Inc. | Conditions: Platinum-resistant Ovarian Cancer, Endometrial Cancer | Phase 1 | Status: TERMINATED